Health ❯Healthcare ❯Pharmaceuticals ❯Drug Development

Combination Therapy

Padcev and Keytruda Combo Extends Survival in Bladder Cancer Trial

Interim topline results have prompted planned discussions with health authorities for potential regulatory filings.

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

New Triple-Drug Regimen Boosts Survival in PIK3CA-Mutant HR+ HER2- Breast Cancer